IN BRIEF: Genedrive shares up as UK government grant received

Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Awarded a ...

Alliance News 16 June, 2023 | 8:27AM
Email Form Facebook Twitter LinkedIn RSS

Genedrive PLC - Manchester, England-based point-of-care molecular diagnostics company - Awarded a multi-partner grant for the validation of its CYP2X19 ID kit from Innovate UK and the UK government Innovation Accelerator programme. Says the 'Devote' grant will allow it to offer critical clinical tests in NHS settings.

Chief Executive Officer David Budd says: "Devote is an amazing opportunity to engage formally with a health system like the NHS to demonstrate the effectiveness of a new diagnostic approach. Access to the Acute Medicine Unit in real time has considerable value to Genedrive as further funding would allow us to progress ongoing product development quickly and efficiently, and would support the pathway to clinical validation of our Genedrive CYP2C19 ID kit."

Current stock price: 18.56 pence each, up 7.6% on Friday morning in London

12-month change: down 11%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Genedrive PLC 1.83 GBX -8.66 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures